Early outcomes of aflibercept intravitreal injection treatment in naive patients with wet age-related macular degeneration

Session Details

Session Title: Free Paper Session 4: AMD II

Session Date/Time: Thursday 07/09/2017 | 11:00-12:30

Paper Time: 12:00

Venue: Room 111

First Author: : M.Dogan TURKEY

Co Author(s): :    M. Sabaner                             

Abstract Details

Purpose:

To investigate early outcomes of intravitreal aflibercept injection according to the naive treatment status in wet age-related macular degeneration (wet-AMD) patients.

Setting:

Afyon Kocatepe University, Faculty of Medicine, Department of Ophthalmology, Afyonkarahisar, Turkey

Methods:

Treatment of wet AMD naive eyes with aflibercept (Eylea 40mg/ml Bayer, Germany) intravitreal injections, from 01/09/2016 to 31/02/2017. All patients had classic CNV type with a 3.8±0.78 months follow-up. Aflibercept was administered as initial 3 consecutive monthly injections, with fixed 1 monthly control examination. The primary outcome was the percentage of patients who maintained or gained visual acuity. Secondary outcomes were mean change in BCVA, changes Spectral-domain optical coherence tomography (SD-OCT) of morphological parameters; central macular thickness (CMT), total macular volume (TMV), central subfield volume (CSV) and choroidal thickness (CT).

Results:

31 eyes of 30 patients were suitable for the analysis. The mean age was 71.06±10.69 years old, with 47% females. At month 1, 84% of patients maintained visual acuity, a mean reduction in CMT of 135.65±76.93 µm (p<0.001), a mean reduction in TMV of 1.49±0.81 mm3 (p<0.001), a mean reduction in CSV of 0.07±0.04 mm3 (p<0.001), a mean reduction in CT of 18.81±1.34 µm (p=0.196), and BCVA significantly improved from 1.17±0.58 logMAR to 0.94±0.57 logMAR (p=0.135). At mean 6 months, 81% of patients maintained visual acuity, a mean reduction in CMT of 136.81±70.64 µm (p<0.001), a mean reduction in TMV of 1.48±0.82 mm3 (p<0.001), a mean reduction in CSV of 0.08 ±0.04 mm3 (p<0.001), a mean reduction in CT of 21.39±0.11 µm (p=0.146) and BCVA significantly improved from 1.17±0.58 logMAR to 0.98±0.54 logMAR (p=0.193). During the selected period, patients received a mean of 4.03±0.53 injections. No significant differences parameter of BCVA, CMT, CSV and CT between first and sixth months (p>0.001).

Conclusions:

Intravitreal aflibercept injection is an effective therapy for treatment naive patients with wet AMD in routine clinical practice. Aflibercept serves as an early anatomic and functional effective and safe treatment of wet AMD.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy